Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Lilly licenses Lycia’s LYTAC protein degrader platform

by Megha Satyanarayana
August 30, 2021 | A version of this story appeared in Volume 99, Issue 31

Eli Lilly and Company will license Lycia Therapeutics’ lysosome-based protein degrader technology for $35 million and up to $1.6 billion in future payments. With its lysosomal targeting chimera (LYTAC) technology, Lycia aims to create small molecules and antibodies targeting difficult-to-drug proteins, including cell surface receptors and secreted proteins. The technology was developed by chemical biologist Carolyn Bertozzi at Stanford University. She has resigned her board seat at Lilly.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.